

BALTIMORE

2002 Annual Members Meeting

OA held its annual members meeting in June with the vibrant inner harbor of Baltimore as its backdrop. Sponsored by Amgen, Immunex, MGI and Roche, the meeting was well attended by physician members and their guests. On the following pages, please enjoy the photos and descriptions of the meetings and focus groups.



AMGEN

Dr. Corey Langer from Fox Chase Cancer Centers spoke on Aranesp giving an overview of the oncology clinical data to the OA members. Dr. Langer reviewed the Phase I, Phase II and Phase III studies which showed Aranesp having a longer half-life compared to that of recombinant human erythropoietin. This longer half-life

allowed for flexible dosing schedules such as once weekly or once every two weeks for those chemotherapy patients requiring treatment. He also presented data of the ongoing trials evaluating the safety and efficacy of Aranesp of an every 3 or 4 week setting.

Aranesp has significantly reduced red cell transfusion requirements in cancer patients undergoing chemotherapy. It is well tolerated and its side-effect profile was similar to those patients receiving placebo. In summary, Aranesp appeared to produce an overall response similar to recombinant human erythropoietin in patients receiving chemotherapy but can be dosed less frequently.

